HIV patients retention and attrition in care and their determinants in Ethiopia: a systematic review and meta-analysis.
Attrition
Ethiopia
HIV patient
Retention
Systematic review
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
22 Jun 2020
22 Jun 2020
Historique:
received:
07
12
2018
accepted:
17
06
2020
entrez:
24
6
2020
pubmed:
24
6
2020
medline:
20
8
2020
Statut:
epublish
Résumé
There is paucity of evidence on the magnitude of HIV patients' retention and attrition in Ethiopia. Hence, the aim of this study was to determine the pooled magnitude of HIV patient clinical retention and attrition and to identify factors associated with retention and attrition in Ethiopia. Systematic review and meta-analysis were done among studies conducted in Ethiopia using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Both published and unpublished studies conducted from January 1, 2005 to June 6th, 2019 were included. Major databases and search engines such as Google Scholar, PUBMED, African Journals Online (AJOL) and unpublished sources were searched to retrieve relevant articles. Data were assessed for quality, heterogeneity and publication bias. Analysis was conducted using STATA version 14 software. From a total of 45 studies 546,250 study participants were included in this review. The pooled magnitude of retention in care among HIV patients was 70.65% (95% CI, 68.19, 73.11). The overall magnitude of loss to follow up 15.17% (95% CI, 11.86, 18.47), transfer out 11.17% (95% CI, 7.12, 15.21) and death rate were 6.75% (95% CI, 6.22, 7.27). Major determinants of attrition were being unmarried patient (OR 1.52, 95% CI: 1.15-2.01), non-disclosed HIV status (OR 6.36, 95% CI: 3.58-11.29), poor drug adherence (OR 6.60, 95% CI: 1.41-30.97), poor functional status (OR 2.11, 95% CI: 1.33-3.34), being underweight (OR 2.21, 95% CI: 1.45-3.39) and advanced clinical stage (OR 1.85, 95% CI: 1.36-2.51). Whereas absence of opportunistic infections (OR 0.52, 95% CI: 0.30-0.9), normal hemoglobin status (OR 0.29, 95% CI: 0.20-0.42) and non-substance use (OR 95% CI: 0.41, 0.17-0.98) were facilitators of HIV patient retention in clinical care. The level of retention to the care among HIV patients was low in Ethiopia. Socio-economic, clinical, nutritional and behavioral, intervention is necessary to achieve adequate patient retention in clinical care.
Sections du résumé
BACKGROUND
BACKGROUND
There is paucity of evidence on the magnitude of HIV patients' retention and attrition in Ethiopia. Hence, the aim of this study was to determine the pooled magnitude of HIV patient clinical retention and attrition and to identify factors associated with retention and attrition in Ethiopia.
METHODS
METHODS
Systematic review and meta-analysis were done among studies conducted in Ethiopia using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Both published and unpublished studies conducted from January 1, 2005 to June 6th, 2019 were included. Major databases and search engines such as Google Scholar, PUBMED, African Journals Online (AJOL) and unpublished sources were searched to retrieve relevant articles. Data were assessed for quality, heterogeneity and publication bias. Analysis was conducted using STATA version 14 software.
RESULT
RESULTS
From a total of 45 studies 546,250 study participants were included in this review. The pooled magnitude of retention in care among HIV patients was 70.65% (95% CI, 68.19, 73.11). The overall magnitude of loss to follow up 15.17% (95% CI, 11.86, 18.47), transfer out 11.17% (95% CI, 7.12, 15.21) and death rate were 6.75% (95% CI, 6.22, 7.27). Major determinants of attrition were being unmarried patient (OR 1.52, 95% CI: 1.15-2.01), non-disclosed HIV status (OR 6.36, 95% CI: 3.58-11.29), poor drug adherence (OR 6.60, 95% CI: 1.41-30.97), poor functional status (OR 2.11, 95% CI: 1.33-3.34), being underweight (OR 2.21, 95% CI: 1.45-3.39) and advanced clinical stage (OR 1.85, 95% CI: 1.36-2.51). Whereas absence of opportunistic infections (OR 0.52, 95% CI: 0.30-0.9), normal hemoglobin status (OR 0.29, 95% CI: 0.20-0.42) and non-substance use (OR 95% CI: 0.41, 0.17-0.98) were facilitators of HIV patient retention in clinical care.
CONCLUSION
CONCLUSIONS
The level of retention to the care among HIV patients was low in Ethiopia. Socio-economic, clinical, nutritional and behavioral, intervention is necessary to achieve adequate patient retention in clinical care.
Identifiants
pubmed: 32571232
doi: 10.1186/s12879-020-05168-3
pii: 10.1186/s12879-020-05168-3
pmc: PMC7310275
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
439Références
PLoS One. 2014 Aug 13;9(8):e104961
pubmed: 25119665
Trop Med Int Health. 2008 Mar;13(3):328-33
pubmed: 18298607
J Int Assoc Provid AIDS Care. 2013 Jan-Feb;12(1):32-8
pubmed: 22993233
Lancet. 2011 Oct 29;378(9802):1572-9
pubmed: 21951656
BMC Infect Dis. 2018 Feb 20;18(1):83
pubmed: 29458343
PLoS One. 2015 Jun 26;10(6):e0130649
pubmed: 26114436
PLoS One. 2014 May 07;9(5):e96867
pubmed: 24806474
AIDS Patient Care STDS. 2013 Dec;27(12):681-91
pubmed: 24320013
Open Forum Infect Dis. 2014 Jun 19;1(1):ofu039
pubmed: 25734107
PLoS One. 2017 Mar 30;12(3):e0173928
pubmed: 28358828
BMC Res Notes. 2018 May 10;11(1):287
pubmed: 29747698
Global Health. 2014 May 27;10:43
pubmed: 24886686
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):e64-71
pubmed: 23429504
PLoS Med. 2011 Oct;8(10):e1001111
pubmed: 22039357
J Int Assoc Provid AIDS Care. 2017 Jan/Feb;16(1):75-80
pubmed: 26518590
Glob Health Action. 2016 Jan 12;9:29943
pubmed: 26765104
AIDS Res Treat. 2017;2017:5415298
pubmed: 29214077
HIV AIDS (Auckl). 2015 May 28;7:167-74
pubmed: 26064071
J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):375-385
pubmed: 30570525
Infect Dis Poverty. 2015 Jun 01;4:27
pubmed: 26034602
PLoS One. 2017 Jan 20;12(1):e0169651
pubmed: 28107430
J Int AIDS Soc. 2016 Mar 21;19(1):20662
pubmed: 27005750
PLoS Med. 2011 Jul;8(7):e1001056
pubmed: 21811403
PLoS Med. 2017 Nov 28;14(11):e1002463
pubmed: 29182641
PLoS Med. 2007 Oct 16;4(10):e298
pubmed: 17941716
BMC Public Health. 2018 Jul 20;18(1):896
pubmed: 30029598
South Afr J HIV Med. 2015 Jul 02;16(1):367
pubmed: 29568589
Int J Infect Dis. 2017 Jul;60:70-76
pubmed: 28533167
BMC Health Serv Res. 2011 Apr 18;11:81
pubmed: 21501509
PLoS One. 2015 Sep 04;10(9):e0136117
pubmed: 26340271
AIDS Behav. 2018 Mar;22(3):752-764
pubmed: 27990582
HIV AIDS (Auckl). 2019 Apr 18;11:77-82
pubmed: 31118825
Trop Med Int Health. 2010 Jun;15 Suppl 1:1-15
pubmed: 20586956
PLoS One. 2017 Jun 16;12(6):e0179533
pubmed: 28622361
BMJ Open. 2013 Oct 25;3(10):e003499
pubmed: 24163204
J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):414-9
pubmed: 26181823
PLoS One. 2016 Feb 22;11(2):e0149584
pubmed: 26901765
Pac AIDS Alert Bull. 1999;(18):15-6
pubmed: 12349391
PLoS One. 2013;8(3):e59197
pubmed: 23527132
BMC Infect Dis. 2018 Jun 18;18(1):280
pubmed: 29914400
N Am J Med Sci. 2014 Sep;6(9):453-9
pubmed: 25317390
J Int Assoc Physicians AIDS Care (Chic). 2010 Sep-Oct;9(5):318-24
pubmed: 20923956
BMC Res Notes. 2018 Oct 25;11(1):761
pubmed: 30359289
Pan Afr Med J. 2014 Feb 03;17:88
pubmed: 25452834
PLoS One. 2018 Jan 26;13(1):e0188488
pubmed: 29373574
PLoS One. 2016 Jun 09;11(6):e0156506
pubmed: 27280404
Pan Afr Med J. 2015 Oct 14;22:138
pubmed: 26889319
HIV AIDS (Auckl). 2016 Apr 26;8:83-92
pubmed: 27175095
PLoS One. 2014 May 14;9(5):e97353
pubmed: 24828585
BMJ Open. 2018 Feb 6;8(2):e016961
pubmed: 29437750
ISRN AIDS. 2012 Jun 14;2012:721720
pubmed: 24052883
Tanzan J Health Res. 2012 Oct;14(4):250-6
pubmed: 26591722
PLoS One. 2018 Jul 11;13(7):e0200505
pubmed: 29995957
Int J Evid Based Healthc. 2015 Sep;13(3):147-53
pubmed: 26317388
BMC Public Health. 2015 Aug 27;15:826
pubmed: 26310943
AIDS Behav. 2019 Sep;23(9):2542-2548
pubmed: 30989552
Antivir Ther. 2016;21(5):385-96
pubmed: 26731316
J Family Med Prim Care. 2016 Apr-Jun;5(2):266-269
pubmed: 27843825
BMJ Glob Health. 2017 Aug 6;2(3):e000325
pubmed: 29082011
J Acquir Immune Defic Syndr. 2015 May 1;69(1):98-108
pubmed: 25942461
BMC Public Health. 2015 May 03;15:462
pubmed: 25934178
BMC Infect Dis. 2019 Feb 4;19(1):107
pubmed: 30717705
BMC Health Serv Res. 2014 Jan 29;14:45
pubmed: 24475889
BMC Infect Dis. 2019 Jul 22;19(1):654
pubmed: 31331280
AIDS Res Treat. 2012;2012:375217
pubmed: 22461979
PLoS One. 2016 Jun 07;11(6):e0156619
pubmed: 27272890
PLoS One. 2016 Dec 20;11(12):e0168323
pubmed: 27997931
BMC Public Health. 2013 Sep 22;13:867
pubmed: 24053770
BMC Res Notes. 2019 Apr 18;12(1):232
pubmed: 30999924
AIDS Care. 2016 Aug;28(8):1018-22
pubmed: 26829232
BMC Pediatr. 2014 Oct 04;14:250
pubmed: 25280967
BMC Res Notes. 2018 Jun 5;11(1):351
pubmed: 29871671
BMC Res Notes. 2019 Feb 28;12(1):111
pubmed: 30819236
Trop Med Int Health. 2012 Dec;17(12):1509-20
pubmed: 22994151
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120